Login to Your Account

Pirfenidone Case Study

FDA vs EMA: One Molecule, Two Different Conclusions

By Brian Orelli

Monday, December 27, 2010
Earlier this month, the European Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for InterMune Inc.'s idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone). The European Medicines Agency (EMA) is expected to ratify the decision in a few months, clearing the way for InterMune to launch the drug in Europe. (See BioWorld Today, Dec. 20, 2010.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription